Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Inhibition of formation of α-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease.

Faria C, Jorge CD, Borges N, Tenreiro S, Outeiro TF, Santos H.

Biochim Biophys Acta. 2013 Aug;1830(8):4065-72. doi: 10.1016/j.bbagen.2013.04.015. Epub 2013 Apr 19.

PMID:
23608058
2.

Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.

Chaari A, Hoarau-Véchot J, Ladjimi M.

Int J Biol Macromol. 2013 Sep;60:196-205. doi: 10.1016/j.ijbiomac.2013.05.032. Epub 2013 Jun 5. Review. Erratum in: Int J Biol Macromol. 2014 Jul;68:274.

PMID:
23748003
3.

DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Batelli S, Albani D, Rametta R, Polito L, Prato F, Pesaresi M, Negro A, Forloni G.

PLoS One. 2008 Apr 2;3(4):e1884. doi: 10.1371/journal.pone.0001884.

4.

Novel suppressors of alpha-synuclein toxicity identified using yeast.

Liang J, Clark-Dixon C, Wang S, Flower TR, Williams-Hart T, Zweig R, Robinson LC, Tatchell K, Witt SN.

Hum Mol Genet. 2008 Dec 1;17(23):3784-95. doi: 10.1093/hmg/ddn276. Epub 2008 Sep 4.

5.

Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E.

PLoS One. 2008 Sep 4;3(9):e3135. doi: 10.1371/journal.pone.0003135.

6.

Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.

Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN.

J Mol Biol. 2005 Sep 2;351(5):1081-100.

PMID:
16051265
7.
8.

The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.

Chaari A, Eliezer D, Ladjimi M.

Int J Biol Macromol. 2016 Feb;83:433-41. doi: 10.1016/j.ijbiomac.2015.10.089. Epub 2015 Nov 19.

9.

Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.

Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, Caldwell GA, McCaffery JM, Rochet JC, Lindquist S.

Dis Model Mech. 2010 Mar-Apr;3(3-4):194-208. doi: 10.1242/dmm.004267. Epub 2009 Dec 28.

10.

Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.

Luna E, Luk KC.

FEBS Lett. 2015 Dec 21;589(24 Pt A):3749-59. doi: 10.1016/j.febslet.2015.10.023. Epub 2015 Oct 23. Review.

11.

Chemical induction of Hsp70 reduces α-synuclein aggregation in neuroglioma cells.

Kilpatrick K, Novoa JA, Hancock T, Guerriero CJ, Wipf P, Brodsky JL, Segatori L.

ACS Chem Biol. 2013 Jul 19;8(7):1460-8. doi: 10.1021/cb400017h. Epub 2013 May 1.

12.

Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly.

Luk KC, Mills IP, Trojanowski JQ, Lee VM.

Biochemistry. 2008 Nov 25;47(47):12614-25. doi: 10.1021/bi801475r.

13.
14.

Potential applications of stress solutes from extremophiles in protein folding diseases and healthcare.

Jorge CD, Borges N, Bagyan I, Bilstein A, Santos H.

Extremophiles. 2016 May;20(3):251-9. doi: 10.1007/s00792-016-0828-8. Epub 2016 Apr 12. Review.

PMID:
27071404
15.

Sequestration of a β-hairpin for control of α-synuclein aggregation.

Mirecka EA, Shaykhalishahi H, Gauhar A, Akgül Ş, Lecher J, Willbold D, Stoldt M, Hoyer W.

Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4227-30. doi: 10.1002/anie.201309001. Epub 2014 Mar 12.

PMID:
24623599
16.

Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae.

Soper JH, Roy S, Stieber A, Lee E, Wilson RB, Trojanowski JQ, Burd CG, Lee VM.

Mol Biol Cell. 2008 Mar;19(3):1093-103. doi: 10.1091/mbc.E07-08-0827. Epub 2008 Jan 2. Erratum in: Mol Biol Cell. 2008 May;19(5):2348.

17.

α-Synuclein aggregation and modulating factors.

Paleologou KE, El-Agnaf OM.

Subcell Biochem. 2012;65:109-64. doi: 10.1007/978-94-007-5416-4_6. Review.

PMID:
23225002
18.

Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract.

Shaltiel-Karyo R, Davidi D, Frenkel-Pinter M, Ovadia M, Segal D, Gazit E.

Biochim Biophys Acta. 2012 Oct;1820(10):1628-35. doi: 10.1016/j.bbagen.2012.04.021. Epub 2012 May 2.

PMID:
22575665
19.

Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease.

Raichur A, Vali S, Gorin F.

Neuroscience. 2006 Oct 27;142(3):859-70. Epub 2006 Aug 22.

PMID:
16920272
20.

Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones.

Hinault MP, Cuendet AF, Mattoo RU, Mensi M, Dietler G, Lashuel HA, Goloubinoff P.

J Biol Chem. 2010 Dec 3;285(49):38173-82. doi: 10.1074/jbc.M110.127753. Epub 2010 Sep 16.

Supplemental Content

Support Center